![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, May 07, 2016 10:04:20 AM
I know you don't think I was comparing my knowledge with that of Jed Wolcott's. But Jed has had to throw in the towel on some of the largest biotech trials -- even as the investors thought that his very testing of their product was a sign that there was something significant being produced by their company. So simply throwing out a researcher's name as if it lends some kind of magical quality to the biologic he is testing simply is not logical. Is he still researching BAVI? I don't know. Do you? Will we be told in a timely manner that he is no longer researching BAVI? I don't know; do you?
But regardless of who's still researching BAVI, the optimists on this Board have to contend with the fact that management has not given us a crumb of hard evidence that there's more to this story after so many years. They leave us only with more questions: questions that are answered hypothetically by writers who offer optimistic scenarios; these are good people but they are generally the same good people who assured us that SUNRISE was a slam dunk.
When I hear, for instance, that King said in the catastrophic presser in February that BAVI had performed as expected, there has been an entire narrative of hope created which would lead one to believe that he was signaling that BAVI continues on the path to success. Yet, in that same presser, he said that the termination of SUNRISE was a huge disappointment. He gave no qualifications to that statement. One could argue, I guess, that his relating that BAVI testing would continue with immuno synergies was indirectly stating that the path to success is still on the straight and narrow. But he never said that. We are left with conjecture, but nothing more.
You make the failure of SUNRISE to be a small blip on a radar screen. It wasn't: not for this company. A lot of scarce resources were poured into this trial. We hung, in the investment world (ask the Board member who wrote the excellent stories about BAVI on Seeking Alpha), the reputation of BAVI on this Phase III. Added to the other negative perceptions of the Street regarding this company and this was a solid hit to the hull of the USS PPHM. Can the damage be repaired? I wouldn't rule it out, but I am overloaded with skepticism.
My slim retention of an ounce of hope hangs on the possibility that, for whatever reason, BAVI requires more time to work than what its been given the ability to demonstrate. This was offered as a possibility after the failure with whatever the Defense Department was using it to test as well as something to do (years ago) with either pancreatic or liver cancer (I cannot remember).
I agree with you that the field is too dynamic for outlandish expectations. But that argument works against us as well. The field of cancer research is moving so quickly that whatever BAVI can or cannot do may be obsolete by the time it registers any hard successes.
Bottom line: a small biotech does not throw its meager resources into a very rare Phase III lightly (unless this management is even more inept that what I even have considered). Forcing a small biotech like PPHM to shutdown a trial in the biotech investment world is devastating. I don't think this point has been made sufficiently clear.
I'm in no position, by the way, to call anyone a fool. I've stuck with this investment since 2000. I've read your posts pre-February and admired your putting yourself on the line in defense of BAVI and PPHM. I've just reached a different conclusion 10 weeks after the SUNRISE shutdown. I hope and pray that I'm wrong. I just cannot mentally embrace an optimistic scenario regarding BAVI at this juncture. AVID is real. BAVI is a potential citizen in a far away country. Sell BAVI (if it's even possible) and turn PPHM into a manufacturing power house. I think that is the best investment going forward.
Good luck to you and all of us.
Recent CDMO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM